Trevena stock trades at USD 0.01 as historical figures surface

Published on 09/28/2026 at 23:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Trevena stock posted USD 283,000 in Q3 fiscal 2024 revenue, while GAAP EPS was negative USD 5.79. The biotech develops central nervous system medicines.

TRVN, US89365K1007, Illustration mit AI erstellt.

Trevena stock (ISIN US89365K1007) was last at USD 0.01 on OTC Markets on September 25, 2026, at 4:00 p.m. ET. The quotation gives investors a market reference while the company's reported operating figures remain historical.

Historical revenue stays limited

Yahoo Finance lists Trevena's Q3 fiscal 2024 revenue at USD 283,000 and earnings at negative USD 4.94 million. The same page shows a GAAP EPS result of negative USD 5.79 against a consensus estimate of negative USD 7.75 for that quarter.

The comparison is important because the actual GAAP EPS was USD 1.96 less negative than the estimate, while revenue remained a small absolute figure. Yahoo Finance also lists a Q3 fiscal 2024 profit margin of negative 1,745.23 percent.

Biotechnology pipeline defines the company

Trevena is a biotechnology company focused on medicines for central nervous system disorders. Its development portfolio includes OLINVYK, an oliceridine injection for moderate-to-severe acute pain, alongside investigational candidates for migraine and chronic pain.

The company profile identifies Trevena as a US business founded in 2007 with 23 full-time employees. That scale places the USD 283,000 Q3 fiscal 2024 revenue figure in the context of a small research-driven drug developer rather than a diversified pharmaceutical group.

Price remains at USD 0.01

The reference quote for Trevena stock was USD 0.01 on September 25, 2026, at 4:00 p.m. ET. Daily change was 0.00 percent, so the snapshot supplies a neutral price signal rather than a directional trading catalyst.

For investors, the key distinction is between the dated market quotation and the historical operating record. Trevena's Q3 fiscal 2024 revenue, negative USD 5.79 GAAP EPS and negative USD 4.94 million earnings remain the clearest quantified markers in the available company record.